MedTrace Logo

Stereotactic Radiosurgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer

NCT00852644 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2018-05-11

Study results available
· View outcomes & findings →

Summary

RATIONALE: Stereotactic radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue.

PURPOSE: This phase I trial is studying the side effects and best dose of stereotactic radiosurgery in treating patients with stage I or stage II non-small cell lung cancer.

Conditions

Interventions

PROCEDURE

computed tomography

Standard CT scans

RADIATION

fludeoxyglucose F 18

standard doses with CT scans

RADIATION

hypofractionated radiation therapy

4 doses over 2 weeks

RADIATION

stereotactic radiosurgery

CyberKnife radiosurgery

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Boston Medical Center

    lead OTHER

Principal Investigators

  • Minh Tam Truong, MD · Boston Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2013-06-30
Completion
2016-08-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00852644 on ClinicalTrials.gov